From October 1 breast cancer drug Nolvadex (Tamoxifen) will be available on the Pharmaceutical Benefits Scheme (PBS) to prevent breast cancer, at present it is only subsidised for treating breast ...
AstraZeneca will stop selling its breast cancer drug Nolvadex (tamoxifen) by the end of June, according to a letter posted on the FDA’s Web site this week. “As you know, currently there are numerous ...
Tamoxifen (Nolvadex) is an antiestrogen, prescribed for breast cancer. It is also used for infertility, gynecomastia, ductal carcinoma either alone or with other medications. It blocks the actions of ...
Breast cancer patients will soon have a new generic treatment. The Food and Drug Administration has given Aurobindo Pharma’s joint venture, Eugia Pharma the green light for tamoxifen citrate tablets ...
March 2, 2005 — The U.S. Food and Drug Administration (FDA) approved in December 2004 revisions to safety labeling to advise healthcare professionals of the following changes: use of hydroxyzine ...
AstraZeneca is discontinuing US sales of its cancer drug Nolvadex (tamoxifen) from June, after mounting competition from generic products has substantially eroded sales of the brand. AstraZeneca is ...
From October 1 breast cancer drug Nolvadex (Tamoxifen) will be available on the Pharmaceutical Benefits Scheme (PBS) to prevent breast cancer, at present it is only subsidised for treating breast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results